Abvc Biopharma Inc Stock Price, News & Analysis

Welcome to our dedicated page for Abvc Biopharma news (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on Abvc Biopharma stock.

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company developing botanically based therapeutics and a medical device across oncology/hematology, central nervous system disorders, and ophthalmology. The ABVC news feed on Stock Titan brings together company-issued updates and regulatory disclosures that highlight how its pipeline and partnerships are progressing.

Readers can follow announcements on clinical milestones, such as completion of Phase II trials for CNS candidates like ABV-1504 in major depressive disorder and the advancement of ADHD Phase IIb studies at sites in the United States and Taiwan. News items also cover regulatory developments, including US FDA Investigational New Drug (IND) approvals for oncology programs targeting triple negative breast cancer, non-small cell lung cancer, myelodysplastic syndrome, and pancreatic cancer, as well as approvals from regulators in other jurisdictions.

ABVC frequently reports on global licensing agreements that shape its business model. Coverage includes multi-year deals with AiBtl BioPharma Inc. for CNS assets, ForSeeCon Eye Corporation for ophthalmology products including Vitargus®, and OncoX BioPharma Inc. for oncology and hematology products, along with related cash payments, share-based consideration, and potential royalty structures. Updates on these collaborations provide context on how ABVC seeks to translate its R&D into potential future revenue streams.

Investors can also review news about intellectual property achievements, such as patents granted in the United States, Taiwan, and Australia for Polygala extract-based CNS treatments and ophthalmology technologies, and about subsidiary activities at BioKey, Inc. and AiBtl BioPharma Inc. For an integrated view of ABVC’s evolving pipeline, licensing strategy, and financial milestones, this news page offers a centralized snapshot of the company’s publicly reported developments.